Francesco Schettini
Research group
- Translational genomics and targeted therapies in solid tumours Post-doctoral researcher (R2A)
About me
Medical Oncology Specialist since July 2018, with main clinical focus on breast cancer and hereditary cancers. Currently postdoctoral researcher (R2) at the August Pi i Sunyer Biomedical Research Institute in Barcelona, with particular focus on hormone receptor positive and HER2-low breast cancer. Member of the European, Italian and Spanish associations of medical oncology (ESMO, AIOM, SEOM) and of the cooperative research groups SOLTI and GIM. Member of the Order of Doctors of Barcelona (affiliation number: 59391). Speaker at numerous Italian and international national congresses. Lecturer in non-academic courses in Italy. Winner of the scholarship of the European Society of Medical Oncology "ESMO Fellowship 2020" and of the AIOM "Marco Venturini" Lecture 2020. Author of over 20 articles
Featured publications
-
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT
Authors:Reference: Ebiomedicine 2021. -
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
Authors:Reference: Frontiers In Oncology 2021. -
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer
Authors:Reference: Esmo Open 2021. -
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Authors:Reference: European Journal Of Cancer 2021. -
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
Authors:Reference: Esmo Open 2021. -
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Authors:Reference: Lancet Oncology 2020. -
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Authors:Reference: Cancer Treatment Reviews 2020. -
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Authors:Reference: Lancet Oncology 2019.
Featured Projects
-
Dissecting the clinicopathological and molecular features of metastatic HER2-low breast cancer
Principal investigator: Aleix Prat AparicioFunder: Astra Zeneca (Patrocinador)Duration: 01/01/2021 - 30/06/2022 -
Extracellular vesicles in cancer development, progression and drug resistance: potential biomarkers and therapeutic targets
Principal investigator: Stefania Catalano, Mario GiulianoFunder: Italian Ministry of University and Research (MIUR) (Programa financiador competitivo)Code: 2017EKMFTN_006Duration: 29/08/2019 - 29/08/2022